The way I look at this is if there are no additional safety concerns, FDA are not fussing too much over efficacy given emergence of new variants. I am not a huge advocate of boosting teens but since omicron evades 2 dose efficacy to a good extent, FDA's expedited decision seems correct in hindsight. $Pfizer(PFE)$
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
2
举报
登录后可参与评论

暂无评论